Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)

@article{Dvalos2012CiticolineIT,
  title={Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)},
  author={Antoni D{\'a}valos and Jos{\'e} {\'A}lvarez-Sab{\'i}n and Jos{\'e} Castillo and Exuperio D{\'i}ez-Tejedor and Jos{\'e} M. Ferro and Eduardo Martı́nez-Vila and Joaqu{\'i}n Serena and Tom{\'a}s Segura and V{\'i}tor Tedim Cruz and Jaime Masju{\'a}n and Erik Cobo and Julio J Secades},
  journal={The Lancet},
  year={2012},
  volume={380},
  pages={349-357}
}
BACKGROUND Citicoline is approved in some countries for the treatment of acute ischaemic stroke. The drug has shown some evidence of efficacy in a pooled analysis. We sought to confirm the efficacy of citicoline in a larger trial. METHODS We undertook a randomised, placebo-controlled, sequential trial in patients with moderate-to-severe acute ischaemic stroke admitted at university hospitals in Germany, Portugal, and Spain. Using a centralised minimisation process, patients were randomly… Expand
High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial
TLDR
The findings show no clinical benefit of 25% albumin in patients with ischaemic stroke; however, they should not discourage further efforts to identify effective strategies to protect theIschaemic brain, especially because of preclinical literature showing convincing proof ofprinciple for this outcome. Expand
Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials.
TLDR
This systematic review supports some benefits of citicoline in the treatment of acute ischemic stroke, but, on top of the best treatment available (rtPA),citicoline offers a limited benefit. Expand
Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials
TLDR
It is shown that citicolne cannot reduce long-term mortality and dependence rate in the treatment of acute stroke, and the effective rate of citivoline may be not better than that of controls but with reliable safety. Expand
Citicoline for treating people with acute ischemic stroke.
TLDR
Overall, either serious or non-serious adverse events - central nervous system, gastrointestinal, musculoskeletal, etc - were poorly reported and harms may have been underestimated. Expand
Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials
This study was to evaluate the efficacy and safety of early application of citicoline in the treatment of patients with acute stroke by meta-analysis. Randomized controlled trials published until MayExpand
Neuroaid Efficacy on Stroke Recovery A Double-Blind , Placebo-Controlled , Randomized Study
S troke is a major cause of death and disability. Despite extensive research efforts, only a limited number of treatment options have been shown to improve functional outcome after stroke, whichExpand
Citicoline for the Treatment of Head Injury: A Systematic Review andMeta-analysis of Controlled Clinical Trials
TLDR
The effect of citicoline has been diluted across time in parallel with the improvement of the standard of care of this kind of patient, as demonstrated by the cumulative meta-analysis technique. Expand
A Comparative Study on the Effect of Citicoline on Acute Ischemic and Hemorrhagic Stroke
TLDR
Based on the findings of this study, the use of citincoline in acute stroke patients exerted no significant effect in the disease treatment in the short term, however, the long-term administration of this medication could result in significant impacts on the treatment of the patients, especially those with ischemic stroke, and improvement of their efficacy. Expand
How effective is citicoline for acute ischaemic stroke?
TLDR
The International Citicoline Trial on acUte Stroke (ICTUS) trial aimed to find out whether neurovascular protection and repair with citicoline would improve recovery from acute ischaemic stroke, and found it safe, well tolerated, and eff ective in human beings. Expand
Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial
TLDR
When used as part of treatment for acute cerebral infarction, vinpocetine improves patients’ cerebral blood flow, cognitive quality, neurological functions, and QOL, and could be an effective and safe component of treatment regimen in a Chinese population. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
TLDR
Despite the increased risk of intracranial haemorrhage, thrombolysis with alteplase at a dose of 0·9 mg/kg in selected patients may lead to a clinically relevant improvement in outcome. Expand
Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.
TLDR
How this trial was designed and in particular how the simultaneous objectives of taking into account three assessment scales, performing a series of interim analyses and conducting treatment allocation and adjusting the analyses to account for prognostic factors were addressed are described are described. Expand
A randomized dose-response trial of citicoline in acute ischemic stroke patients
TLDR
This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment and appears to improve functional outcome and reduce neurologic deficit with 500 mg ofciticoline appearing to be the optimal dose. Expand
A randomized efficacy trial of citicoline in patients with acute ischemic stroke.
TLDR
Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke who were enrolled in this trial, and post hoc analyses indicate that there may be a subgroup of Patients with moderate to severe strokes who would benefit. Expand
Oral Citicoline in Acute Ischemic Stroke: An Individual Patient Data Pooling Analysis of Clinical Trials
TLDR
Treatment with oral citicoline within the first 24 hours after onset in patients with moderate to severe stroke increases the probability of complete recovery at 3 months, and the overall safety ofciticoline was similar to placebo. Expand
A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients
TLDR
Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses, and post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used. Expand
Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study.
TLDR
A multicenter double-blind placebo-controlled study of cytidine 5'-diphosphocholine (CDP-choline) was conducted to evaluate possible clinical benefits of the drug in patients with acute, moderate to severe cerebral infarction, and CDP- choline showed significant improvements in level of consciousness compared with the placebo-treated group. Expand
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
TLDR
Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4.5 h should be taken to shorten delay in initiation of treatment to increase benefit to a maximum. Expand
Effect of citicoline on ischemic lesions as measured by diffusion‐weighted magnetic resonance imaging
TLDR
A significant inverse relationship between lesion volume change over 12 weeks as measured by MRI and clinical outcome for ischemic stroke is found and supports the role of DWI as a surrogate marker of clinically meaningful lesion progression in stroke clinical trials. Expand
Citicoline: pharmacological and clinical review, 2010 update.
TLDR
This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelsae, and the most important experimental and clinical data are retrieved. Expand
...
1
2
3
4
...